Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Targeted phospholipidomic analysis of synovial fluid as a tool for osteoarthritis deep phenotyping

  • Rocha Loureda, Beatriz
  • Illiano, Anna
  • Calamia, Valentina
  • Pinto, Gabriella
  • Amoresano, Angela
  • Ruiz-Romero, Cristina
  • Blanco García, Francisco J
[Abstract] Objective. The aim of this study was to carry out a targeted phospholipidomic analysis on synovial fluid (SF) from patients with different grades of osteoarthritis (OA) and controls, in order to search for specific phospholipid profiles that may be useful for the deep phenotyping of this disease. Design. Multiple reaction monitoring-mass spectrometry (MRM/MS) was applied to explore the potential phospholipidomic differences in the SF of knee OA patients (n ​= ​15) (subclassified into early- and late-stage OA) and non-OA controls (n ​= ​4). Multivariate statistical analyses conducted by partial least squares discriminant analysis (PLS-DA) and hierarchical clustering analysis (HCA) were performed to identify significantly altered phospholipids in OA, characterize phospholipidomic profiles associated with the radiographic stage of the disease and describe potential endotypes at early stages. Results. Significant discrimination of phospholipid profiles between non-OA controls and the early- and late-stage OA groups were found by PLS-DA and HCA. Compared to SF from non-OA controls, OA patients showed higher levels of most quantified phospholipid species, including phosphatidylcholines (PC), phosphatidylserines and phosphatidylinositols. Furthermore, several PC species showed significant differences in abundance between the two OA subgroups and were negatively correlated with cartilage damage. Finally, two distinct endotypes of early-stage OA were identified based on the phospholipidomic profile of SF. Conclusions. Our data provides a novel insight into the phospholipid profiles of OA synovial fluid, revealing specific alterations associated with the radiographic stage of the disease. This targeted phospholipidomic profiling also facilitated the characterization of two different OA endotypes at early stages of the disease., This work is supported by grants from Fondo Investigación Sanitaria-Spain (PI16/02124, PI17/00404, PI19/01206, PI20/00793 and RETIC-RIER-RD16/0012/0002), integrated in the National Plan for Scientific Program, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of Research - European Regional Development Fund (FEDER) “A way of making Europe”. This study is also supported by AE CICA-INIBIC (ED431E 2018/03) and grants IN607A 2017/11, IN607A 2021/7 and IN607D 2020/10 from Axencia Galega de Innovacion - Xunta de Galicia. The Biomedical Research Networking Center (CIBER) is an initiative from Instituto de Salud Carlos III (ISCIII). The Proteomics Unit of GIR belongs to ProteoRed, PRB3- ISCIII (PT17/0019/0014), Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN607A 2017/11, Xunta de Galicia; IN607A 2021/7, Xunta de Galicia; IN607D 2020/10
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Clinical and molecular data to predict flares in DMARD optimization in rheumatoid arthritis: a randomized, controlled, open-label, non-inferiority trial

  • Blanco García, Francisco J
  • Galindo, Laura
  • Acasuso, Belén
  • Balboa-Barreiro, Vanesa
  • Cañete, Juan D.
  • Fernández-Gutiérrez, Benjamín
  • González-Álvaro, Isidoro
  • Pablos, José L.
  • Bejerano-Herrería, Carmen
  • Silva-Díaz, Maite
  • Rego-Pérez, I.
  • Lourido, Lucía
  • Ruiz-Romero, Cristina
  • Uriarte-Ecenarro, Miren
  • García-Vicuña, Rosario
  • Cuervo, Andrea
  • Ramírez, Julio
  • Celis, Raquel
  • Rodríguez-Rodríguez, Luis
  • Abasolo, Lydia
  • Freites Núñez, Dalifer
  • Martín-López, María
  • De-Toro, Javier
  • Oreiro Villar, Natividad
Clinical trial, [Abstract] Objectives: The aim of this study was to identify robust predictive markers which may help personalize tapering protocols, minimizing flare risk while optimizing long-term disease management in RA patients. Methods: The OPTIBIO trial (EudraCT 2012-004482-40) was a phase IV, randomized, open-label, non-inferiority study conducted in five hospitals in Spain. RA patients in sustained remission on stable bDMARD therapy were randomized 1:1 to standard care or dose reduction. The primary outcome was to compare the proportion of joint flare between baseline and 12 months by a non-inferiority analysis analysed by the intention-to-treat principle and to identify predictors for flare and sustained remission. Results: A total of 195 patients were randomized: 99 to the control group and 96 to the optimization group. Thirty-nine flares occurred (optimization: 22.7%, control: 17.2%), with a risk difference of -5.5% (95% CI: -16.8% to 5.7%; P = 0.33). Two predictive models were developed: one for flares (AUC: 0.84) including 3v-DAS28-CRP, VAS pain, erosions, systolic blood pressure and haemoglobin, and another for sustained remission (AUC: 0.77) including 3v-DAS28-CRP, age and rheumatoid factor. Adding molecular biomarkers improved AUCs to 0.91 and 0.88, respectively. No significant differences in adverse events were observed. Conclusion: bDMARD dose optimization was not non-inferior to standard therapy on the flare rate but demonstrated similar safety. Predictive models for remission and flares were developed, which may help select patients to ensure safe implementation of this strategy, highlighting the need for personalized treatment., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects PMP15/00032 and PMP22/00101 co-funded by the European Regional Development Fund ‘A way to make Europe’; funded by ISCIII, co-funded by the European Union and projects PI20/00793, PI22/01155, PI23/00818 and RD21/0002/0009 funded by Instituto de Salud Carlos III–European Union-NextGenerationEU and supported by CIBER-Consorcio Centro de Investigacion Biomedica en Red- (CB06/01/0040), ISCIII. We also counted upon funding from grant IN607A2021/07 and IN607A_2025/11 from Xunta de Galicia. L.G. is a PhD student supported by Cátedra FSR-UDC, Universidad de A Coruña.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Proteomic profiling of human synovial fluid reveals AKR1C1 as a biomarker of osteoarthritis severity

  • Fernández-Puente, Patricia
  • Paz González, Rocío
  • Calamia, Valentina
  • Picchi, Florencia
  • Quaranta, Patricia
  • Lourido Salas, Lucía María
  • Riva Mendoza, Selva
  • Lotz, Martin
  • Blanco García, Francisco J
  • Ruiz-Romero, Cristina
[Abstract] Pathological changes in the knee joint are reflected in the protein composition of synovial fluid (SF), which is altered in osteoarthritis (OA) and may serve as a source of biomarkers. This study used label-free quantification proteomics to analyze SF protein profiles from individuals with varying grades of cartilage damage and healthy controls. SF samples (n = 61) from healthy knees (grade 0) and OA-affected joints (grades I-IV, Outerbridge score) were analyzed using LC-MS/MS. Feature selection was performed with the Jonckheere-Terpstra nonparametric test. Candidate biomarkers were validated by ELISA in an independent cohort (n = 51), with OA severity graded according to the Kellgren-Lawrence (K/L) scale. Using this approach, nine proteins were significantly differentially expressed between OA and control samples (p < 0.01), showing higher levels in early OA stages compared to moderate and late disease (p < 0.05). Among these, aldo-keto reductase family 1 member C1 (AKR1C1), a protein involved in oxidative stress and autophagy, positively correlated with OA severity in both cohorts. These findings highlight several protein biomarkers with potential utility in early OA diagnosis and monitoring disease progression. Notably, AKR1C1 emerges as a promising diagnostic and prognostic biomarker, warranting further investigation., This work has been funded by Instituto de Salud Carlo s III (ISCIII) through the projects PI20/00793, PI20/01409, PI22/01155, and PI23/00818, and cofunded by the European Union, and also by the grant RD21/0002/0009 financed by Instituto de Salud Carlos III─European Union─NextGenerationEU─Plan de Recuperación transformación y resiliencia. This study has been also supported by grants IN607A2021/07 and IN607D2020/10 from Xunta de Galicia. The Biomedical Research Networking Center (CIBER) is an initiative from Instituto de Salud Carlos III (ISCIII). VC is supported by RICORS-REI RD21/0002/0009.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Integrated Serum Proteomics and Autoantibody Analyses Reveal a Biomarker Signature Predictive of Flare During Biologic Tapering in Rheumatoid Arthritis

  • Blanco García, Francisco J
  • Quaranta, Patricia
  • Domínguez-Guerrero, Pablo
  • Calamia, Valentina
  • Fernández-Puente, Patricia
  • Paz González, Rocío
  • Balboa-Barreiro, Vanesa
  • Noriega-Cobo, Diana M.
  • Galindo, Laura
  • Acasuso, Belén
  • Oreiro Villar, Natividad
  • Rojo, Ricardo
  • Lourido, Lucía
  • Ruiz-Romero, Cristina
[Abstract] Background: Reliable biomarkers predicting which patients with rheumatoid arthritis (RA) can safely undergo biologic tapering are currently lacking. This study aimed to identify circulating protein biomarkers predictive of flare during biologic disease-modifying anti-rheumatic drug tapering in RA. Methods: Baseline serum samples from patients with RA in sustained remission enrolled in the Biologic Optimisation (OPTIBIO) clinical trial were analysed using a two-stage design comprising an exploratory mass spectrometry in a discovery sample subset (n=44, 22 in the optimisation arm and 22 in the control arm), followed by ELISA validation of selected protein biomarkers and anti-cytokine autoantibody profiling in the full cohort (n=194). The primary outcome was a disease flare during follow-up. Results: During follow-up, disease flare occurred in 46.4% of patients in the optimisation arm and 30.9% in the control arm. Within the discovery subset of the optimisation arm, 87 proteins were differentially abundant between patients who flared and those who remained in remission. V-set immunoglobulin-domain-containing 4 (VSIG4) was validated as a biomarker associated with increased flare risk while anti-interferon-γ (anti-IFNγ) autoantibodies were also independently associated with flare. A combined model integrating VSIG4, anti-IFNγ and Disease Activity Score 28-joint count using C reactive protein improved discrimination compared with the clinical model alone (area under the curve (AUC) 0.760 vs 0.666) and showed higher sensitivity and greater potential clinical utility in decision curve analysis. In a secondary exploratory subgroup of patients with prolonged remission, predictive performance further improved (AUC 0.839). Conclusion: These findings identify a promising protein biomarker signature associated with flare during biologic tapering in RA, supporting biomarker-guided risk stratification in treatment optimisation strategies. External validation is required before clinical implementation., This work was supported by the Instituto de Salud Carlos III (ISCIII) through the projects PI20/00793, PI22/01155, PMP22/00101 and PI23/00818 (to FJB and CRR) and co-funded by the European Union. Additional funding was provided by Xunta de Galicia (grants IN607D2020/10, IN607A2021/07, and IN607A2025/11). LL was supported by a Sara Borrell Fellowship (CD19/00229). VC is supported by grant RD24/00070026, funded by the Carlos III Health Institute (ISCIII) and co-financed by the European Union. RPG is supported by Programa de axudas á etapa posdoutoral from Xunta de Galicia (IN606B-2024.22). The Biomedical Research Networking Center (CIBER) is an initiative of ISCIII (CB06/01/0040). This study has been also supported by an Open Access Articles grant from Fundación Pública Galega de Investigación Biomédica INIBIC.